Omnicell, Inc. (NASDAQ:OMCL)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a research note issued on Tuesday. They currently have a $47.00 price target on the stock, up from their previous price target of $43.00. Cantor Fitzgerald’s price objective points to a potential upside of 9.68% from the company’s current price.

OMCL has been the topic of a number of other reports. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, February 22nd. TheStreet upgraded shares of Omnicell from a “c” rating to a “b-” rating in a report on Wednesday, February 15th. CIBC increased their target price on shares of Omnicell from $43.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, ValuEngine upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $46.33.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Shares of Omnicell (NASDAQ:OMCL) traded up 0.35% during trading on Tuesday, reaching $43.00. 107,043 shares of the company traded hands. The company’s market capitalization is $1.60 billion. Omnicell has a 52 week low of $30.35 and a 52 week high of $43.35. The firm’s 50 day moving average price is $41.32 and its 200-day moving average price is $37.88.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, May 4th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.36. Omnicell had a negative net margin of 1.45% and a positive return on equity of 2.66%. The firm had revenue of $150.90 million for the quarter, compared to analyst estimates of $152.63 million. During the same period in the prior year, the business posted $0.35 EPS. The business’s revenue for the quarter was down 12.3% compared to the same quarter last year. Equities analysts anticipate that Omnicell will post $1.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/06/13/omnicell-inc-omcl-receives-overweight-rating-from-cantor-fitzgerald.html.

In other Omnicell news, Director James T. Judson sold 12,148 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $41.50, for a total value of $504,142.00. Following the sale, the director now directly owns 19,130 shares of the company’s stock, valued at approximately $793,895. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 9,900 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $43.00, for a total transaction of $425,700.00. Following the completion of the sale, the chairman now directly owns 208,982 shares in the company, valued at $8,986,226. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,473 shares of company stock worth $2,869,438. 3.75% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in OMCL. Menta Capital LLC purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $380,000. Champlain Investment Partners LLC increased its stake in shares of Omnicell by 21.1% in the fourth quarter. Champlain Investment Partners LLC now owns 1,599,065 shares of the company’s stock worth $54,208,000 after buying an additional 278,495 shares in the last quarter. Greenwood Capital Associates LLC increased its stake in shares of Omnicell by 0.5% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,337 shares of the company’s stock worth $350,000 after buying an additional 50 shares in the last quarter. Azimuth Capital Management LLC increased its stake in shares of Omnicell by 1.1% in the fourth quarter. Azimuth Capital Management LLC now owns 111,910 shares of the company’s stock worth $3,794,000 after buying an additional 1,225 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Omnicell during the fourth quarter worth approximately $788,000. 96.35% of the stock is currently owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.